Publicaciones
- 
                        Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J. Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomesPEDIATRIC BLOOD & CANCER . 71(10): . 
- 
                        Mahnoor S, Molnar C, Velázquez D, Reina J, Llamazares S, Heinen JP, Mora J and Gonzalez C. Human EWS-FLI protein levels and neomorphic functions show a complex, function-specific dose-response relationship in DrosophilaOPEN BIOLOGY . 14(7): 240043-240043. 
- 
                        Sanchez-Guixe E, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González- Pérez A, Mora J and López-Bigas N. Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal TissuesCANCER DISCOVERY . 14(6): 953-964. Nº de citas: 7 
- 
                        Caballero R, Pasten A, Giménez C, Raquel Rodriguez Baladon, Carmona-Jiménez RM, Mora J, Valls-Esteve A, Lustig P, Lombardini F, Balsells S and Krauel L. Beyond Needles: Pioneering Pediatric Care with Virtual Reality (VR) for TIVAD Access in OncologyCancers . 16(12): . Nº de citas: 2 
- 
                        Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effectsFrontiers in oncology . 14: 1380917-1380917. 
- 
                        Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L. Current Status of Fertility Preservation in Pediatric Oncology PatientsCHILDREN-BASEL . 11(5): . Nº de citas: 4 
- 
                        Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 ImmunotherapyCancers . 16(9): . Nº de citas: 1 
- 
                        Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastomaINTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Nº de citas: 11 
- 
                        Llurba E, Crispi F, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E. Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 studyBMJ Open . 14(3): . Nº de citas: 6 
- 
                        Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J. Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based ModelCancers . 16(5): . Nº de citas: 1 
